Editas Medicine (EDIT) Other Non Operating Income (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Other Non Operating Income of -$1000.0 for Q3 2025, up 80.0% year-over-year from -$555.56 in Q3 2024, and up 99.94% quarter-over-quarter from -$1.8 million in Q2 2025.
Powered by 
Analysis
Editas Medicine (EDIT) Other Non Operating Income (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Other Non Operating Income for 11 consecutive years, with -$1000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Non Operating Income rose 80.0% year-over-year to -$1000.0; the TTM figure through Sep 2025 stood at -$2.2 million (down 15521.43% YoY), while the FY2024 annual figure was -$3000.0, up 99.81% from the prior year.
- Other Non Operating Income rose to -$1000.0 in Q3 2025 per EDIT's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $235000.0 in Q2 2022 and bottomed at -$1.8 million in Q2 2025.
- Historically, Other Non Operating Income has averaged -$208666.7 across 5 years, with a median of -$2000.0 in 2021.
- Annual changes were most pronounced in 2022 — Other Non Operating Income surged 23600.0% — and 2025, when it slumped 175700.0%.
- Editas Medicine's Other Non Operating Income stood at -$1000.0 in 2021, then slumped by 300.0% to -$4000.0 in 2022, then tumbled by 250.0% to -$14000.0 in 2023, then soared by 78.57% to -$3000.0 in 2024, then soared by 66.67% to -$1000.0 in 2025.
- Business Quant data shows EDIT's Other Non Operating Income at -$1000.0 in Q3 2025, -$1.8 million in Q2 2025, and -$425000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1.76 Mn |
| Mar 31, 2025 | -425,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | -14,000.00 |
| Jun 30, 2023 | -7,000.00 |
| Mar 31, 2023 | -1.58 Mn |
| Dec 31, 2022 | -4,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 235,000.00 |
| Mar 31, 2022 | -234,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | 19,000.00 |
| Jun 30, 2021 | -1,000.00 |
| Mar 31, 2021 | 21,000.00 |
| Dec 31, 2020 | 3.15 Mn |
| Sep 30, 2020 | -1.40 Mn |